Possessing platform technologies for Stem Cell Platform
Overview
In the face of population ageing, there has been a rise in the
number of organ dysfunctions (wherein the body’s organs stop
working or become frail) as well as neurodegenerative diseases.
Since such phenomena cannot be treated by drugs alone, it is
necessary to develop new treatments to restore normal tissue
function.
DW-MSC’s competitiveness and potential lies in its ability and
capacity to be applied to various technologies and commercialize
stem cells. Our goal is to develop stem cell therapeutics that is
recognized globally through smart stem cell technology integration
with maximized efficacy based on cell and gene technologies.
Points of Differentiation
High Consistency Single donor cell-derived
therapeutics with uniform characteristics, Continuous production
of consistent quality cell therapy products with cGMP-grade cell
bank
Cell & Gene Therapeutics Stem cell
cultivation technology that is completely feeder-free, serum-free,
and animal component-free, Enhanced efficacy via priming(stem cell
pre-processing) and genetic modification
Mass Production Technology 2D & 3D
platform cell culture technologies, Homogeneous cell
characteristics maintained for up to 20 subcultures(cell
passaging)
Open Collaboration Joint development of
therapy for intractable and rare as well as degenerative diseases,
Flexible and versatile business model